Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.56 |
| ▸ | TLR2 | O60603 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MDM4 | O15151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12254867 | 0.94 | TLR2 (0.57) | MDM2TLR2KMT2AMDM4TP53 | |
| SCHEMBL30684555 | 0.93 | TLR2 (0.58) | MDM2TLR2KMT2AMDM4TP53 | |
| SCHEMBL14433000 | 0.92 | TLR2 (0.59) | MDM2TLR2KMT2AMDM4TP53 | |
| SCHEMBL178814 | 0.92 | MDM2 (0.59) | MDM2TLR2KMT2AMDM4TP53 | |
| SCHEMBL29397631 | 0.92 | MDM2 (0.59) | MDM2TLR2KMT2AMDM4TP53 | |
| SCHEMBL1637300 | 0.92 | MDM2 (0.59) | MDM2TLR2KMT2AMDM4TP53 | |
| SCHEMBL1638340 | 0.92 | MDM2 (0.59) | MDM2TLR2KMT2AMDM4TP53 | |
| SCHEMBL29400055 | 0.92 | MDM2 (0.59) | MDM2TLR2KMT2AMDM4TP53 | |
| SCHEMBL30477936 | 0.92 | MDM2 (0.59) | MDM2TLR2KMT2AMDM4TP53 | |
| SCHEMBL1738182 | 0.91 | MDM2 (0.59) | MDM2TLR2KMT2AMDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | claimed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | MDM2 2036/4885TLR2 4097/4885KMT2A 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.